Neoadjuvant immunochemotherapy vs. neoadjuvant targeted therapy plus chemotherapy for EGFR-mutated non-small cell lung cancer: a retrospective study

Abstract Background Adjuvant targeted therapy represents the standard of care for patients with resectable epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Neoadjuvant therapy can improve surgical and survival outcomes. This study aimed to compare the effectiveness...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Feng Li, Chaoqi Zhang, Luyu Huang, Ziming Wang, Guanchao Ye, Zhuoyu Gu, Yu Qi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2026-01-01
coleção:	BMC Cancer
Assuntos:	EGFR NSCLC Neoadjuvant therapy Immunotherapy EGFR-TKIs
Acesso em linha:	https://doi.org/10.1186/s12885-026-15582-6
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!